Extended Data Fig. 5: Changes in cholesterol efflux capacities following LY3475766 administration. | Nature Medicine

Extended Data Fig. 5: Changes in cholesterol efflux capacities following LY3475766 administration.

From: Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

Extended Data Fig. 5

Percent changes in (a) global, (b) ABCA1, and (c) non-ABCA1 cholesterol efflux capacities at day 15 following SC administration of LY3475766 (LY 100 mg, n = 5; LY 300 mg, n = 7; LY 600 mg, n = 4) and day 22 (LY 100 mg, n = 6; LY 300 mg, n = 7; LY 600 mg, n = 4) are shown for LY3475766 dose groups. Data are expressed as least-squares mean (standard error). ABCA1, ATP-binding cassette transporter A1; LY, LY3475766; n, number of participants; SC, subcutaneous.

Source data

Back to article page